Autologous Stem Cell And Non-Stem Cell Based Therapies Market Size (2024 - 2029)

Autologous Stem Cell And Non-Stem Cell Based Therapies Market Analysis

The Autologous Stem Cell And Non-Stem Cell Based Therapies Market size is estimated at USD 5.61 billion in 2024, and is expected to reach USD 11.23 billion by 2029, growing at a CAGR of 14.89% during the forecast period (2024-2029).

Factors such as the rising prevalence of targeted diseases, the introduction of novel autologous stem cell-based therapies in regenerative medicine, and the increase in the geriatric population are expected to boost the market's growth during the forecast period.

There is a significant increase in the geriatric population around the world, which is vulnerable to being affected with various chronic diseases such as cancer, neurodegenerative disorders, and other diseases and hence fuels the demands for autologous stem cell and non-stem cell-based therapies for treatment. For instance, in July 2023, a report published by the Age United Kingdom Organization reported that there were around 11 million individuals aged above 65 years in England in 2023. This number was projected to increase by 10% and 32% by 2024 and 2043, respectively. Similarly, according to the report published by the United Nations Population Fund in India in September 2023, the population of over 60 in India was expected to increase from 149 million in 2022 to around 347 million by 2050. Further, an article published in the Journal of Cells in November 2022 mentioned that stem-cell-based therapy is significantly used for the treatment of various neurological disorders such as Alzheimer’s disease, Parkinson's disease, multiple sclerosis, and other neurological disorders due to the ability of stem cells to replace damaged cells and tissues coupled with anti-inflammatory and immune-modulatory properties. Thus, the growing geriatric population, coupled with an increase in the occurrence of degenerative diseases, which could be treated with the help of stem cell therapy, is expected to contribute to the market's growth during the forecast period.

Stem cell technology is a speedily developing technology that plays a significant role in regenerative medicine. It also serves the disciplines of tissue engineering, developmental cell biology, cellular therapeutics, gene therapy, chemical biology, and nanotechnology.

Stem cells can replace the cells and tissues to treat various conditions, including spinal cord injury, arthritis, and Parkinson's disease. Therefore, wide applications of stem cells can boost their adoption for treating diseases and are expected to boost the market's growth. For instance, in May 2023, an article published in the International Journal of Molecular Sciences mentioned that mesenchymal stem cells are most commonly used for tissue engineering and implantation to treat arthritis. These cells are effective due to the secretion of bioactive molecules, which induce anti-apoptotic, anti-inflammatory, and immunomodulatory responses that boost the regeneration and stimulation of tissue-specific progenitors. Thus, the increasing applications of stem cells in the treatment of various disorders are expected to contribute to the market's growth during the forecast period.

The new approvals concerning autologous stem cell-based therapies are anticipated to increase the adoption of innovative products and boost the market's growth. For instance, in October 2023, Aspen Neuroscience received approval from the United States Food and Drug Administration for fast-track designation for ANPD001, an autologous investigational cell therapy used to treat Parkinson's disease in improving motor function. Additionally, in September 2023, BioLineRx Ltd received the United States Food and Drug Administration approval for Aphexda (motixafortide) along with filgrastim (G-CSF) to induce mobilization of hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.

The aforementioned factors, such as the increase in the geriatric population and applications of autologous stem cell therapy in chronic diseases like arthritis, coupled with new product approvals, are expected to boost the growth of the market studied during the forecast period. However, the high cost of autologous cellular therapies and the need for more skilled professionals are anticipated to hinder the growth of autologous stem cell and non-stem cell-based therapies during the forecast period.

Autologous Stem Cell And Non-Stem Cell Based Therapies Industry Segmentation

As per the scope of the report, autologous stem cell therapy or stem cell transplant uses healthy blood stem cells from one's own body to replace diseased or damaged bone marrow. Non-stem cell-based therapy comprising autologous platelet-rich plasma (PRP) is a treatment that contains fibrin and high concentrations of growth factors and has the potential to improve the healing of chronic wounds.

The market is segmented by type, application, end user, and geography. By type, the market is segmented into autologous stem cells and autologous non-stem cells. By application, the market is segmented into cancer, neurodegenerative disorders, cardiovascular disease, orthopedic diseases, and other applications. By end user, the market is segmented into hospitals, ambulatory surgical centers, and research facilities. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The market provides the value (USD) for the above-mentioned segments.